Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor...(n six continents. -- Kendle is proud ...)

-- Kendle is proud to have worked with 46 of the top 50 global

biopharmaceutical companies to speed their drugs to market.

-- Kendle is one of only two global CROs to have at least 50 percent of

its revenues outside of the United States, according to industry

analyst Jefferies & Company, Inc.

-- Kendle's net service revenues have increased from $44 million for

Fiscal Year 1997 when the company first started trading on NASDAQ to

$283.5 million at the end of 2006.

-- Kendle increased its size by 50 percent from 2006 to 2007 through the

acquisition of the Phase II-IV business of Charles River Clinical

Services, Inc., adding attractive therapeutic expertise, diversifying

its customer base and expanding its capacity to deliver global trials.

-- Kendle's customer-focused approach to delivery of Phase I-IV clinical

development services has resulted in sales growth above the industry

average for three consecutive years, with sales for 2006 at triple the

reported average sector growth rate.

-- Proprietary company quantitative research conducted in 2006 showed

Kendle's reputation as a first-choice partner for Phase III studies

grew significantly with the company perceived as a top three global CRO

in this area, one of the areas of greatest market opportunity in the

CRO industry.

-- Kendle has been recognized as the "Top CRO to Work With" in the Thomson

CenterWatch 2007 Survey of U.S. Investigative Sites and as the "Best

Contract Research Organization" in November 2006 by an independent

panel for Scrip World Pharmaceutical News.

-- As one of the early CROs Kendle is actively shaping the future of our

industry as one of the five founding and active members of the

Association of Clinical Research Organizations (ACRO) established in